482 related articles for article (PubMed ID: 8083714)
1. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies.
Giralt SA; LeMaistre CF; Vriesendorp HM; Andersson BS; Dimopoulos M; Gajewski J; Van Besien K; Mehra R; Przepiorka D; Khouri I
J Clin Oncol; 1994 Sep; 12(9):1923-30. PubMed ID: 8083714
[TBL] [Abstract][Full Text] [Related]
2. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
[TBL] [Abstract][Full Text] [Related]
3. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
Wu DP; Milpied N; Moreau P; Mechinaud-Lacroix F; Mahe B; Le Tortorec S; Rapp MJ; Bourdin S; Mahe JM; Harousseau JL
Bone Marrow Transplant; 1994 Nov; 14(5):751-7. PubMed ID: 7889008
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
Duerst RE; Horan JT; Liesveld JL; Abboud CN; Zwetsch LM; Senf ES; Constine LS; Raubertas RF; Passarell JA; DiPersio JF
Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
[TBL] [Abstract][Full Text] [Related]
5. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease.
Miralbell R; Bieri S; Mermillod B; Helg C; Sancho G; Pastoors B; Keller A; Kurtz JM; Chapuis B
J Clin Oncol; 1996 Feb; 14(2):579-85. PubMed ID: 8636774
[TBL] [Abstract][Full Text] [Related]
6. Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.
Petersen FB; Buckner CD; Appelbaum FR; Sanders JE; Bensinger WI; Storb R; Deeg HJ; Witherspoon RP; Sullivan KM; Clift RA
Bone Marrow Transplant; 1992 Jul; 10(1):83-8. PubMed ID: 1515884
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
Jillella AP; Doria R; Khan K; Zelterman D; Ahmad YH; Smith BR; Holmes W; Becker P; Roberts KB; Rappeport JM
Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947
[TBL] [Abstract][Full Text] [Related]
8. Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation.
Crilley P; Topolsky D; Styler MJ; Bernstein E; Resnick K; Mullaney R; Bulova S; Brodsky I; Marks DI
Bone Marrow Transplant; 1995 Mar; 15(3):361-5. PubMed ID: 7599559
[TBL] [Abstract][Full Text] [Related]
9. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
Demirer T; Weaver CH; Buckner CD; Petersen FB; Bensinger WI; Sanders J; Clift RA; Lilleby K; Anasetti C; Martin P
J Clin Oncol; 1995 Mar; 13(3):596-602. PubMed ID: 7884421
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of etoposide, cyclophosphamide, and total body irradiation in allogeneic bone marrow transplantation for adult patients with hematological malignancies.
Toubai T; Tanaka J; Mori A; Hashino S; Kobayashi S; Ota S; Miura Y; Kato N; Kahata K; Izumiyama K; Yonezumi M; Chiba K; Kondo T; Toyoshima N; Asaka M; Imamura M
Clin Transplant; 2004 Oct; 18(5):552-7. PubMed ID: 15344959
[TBL] [Abstract][Full Text] [Related]
11. Total body irradiation, thiotepa, and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukemia in first or second remission undergoing bone marrow transplantation with HLA-identical siblings.
Zecca M; Pession A; Messina C; Bonetti F; Favre C; Prete A; Cesaro S; Porta F; Mazzarino I; Giorgiani G; Rondelli R; Locatelli F
J Clin Oncol; 1999 Jun; 17(6):1838-46. PubMed ID: 10561223
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow transplantation for advanced acute leukemia: a pilot study of high-energy total body irradiation, cyclophosphamide and continuous infusion etoposide.
Bostrom B; Weisdorf DJ; Kim T; Kersey JH; Ramsay NK
Bone Marrow Transplant; 1990 Feb; 5(2):83-9. PubMed ID: 2107007
[TBL] [Abstract][Full Text] [Related]
13. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
14. Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation.
Blume KG; Long GD; Negrin RS; Chao NJ; Kusnierz-Glaz C; Amylon MD
Bone Marrow Transplant; 1994; 14 Suppl 4():S9-10. PubMed ID: 7728133
[TBL] [Abstract][Full Text] [Related]
15. A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies.
Sobecks RM; Daugherty CK; Hallahan DE; Laport GF; Wagner ND; Larson RA
Bone Marrow Transplant; 2000 Apr; 25(8):807-13. PubMed ID: 10808200
[TBL] [Abstract][Full Text] [Related]
16. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
18. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
Spitzer TR; Cottler-Fox M; Torrisi J; Cahill R; Greenspan A; Lynch M; Deeg HJ
Bone Marrow Transplant; 1989 Sep; 4(5):559-65. PubMed ID: 2676044
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation.
Geller RB; Devine SM; O'Toole K; Persons L; Keller J; Mauer D; Holland HK; Dix SP; Piotti M; Redei I; Connaghan G; Heffner LT; Hillyer CD; Waller EK; Winton EF; Wingard JR
Bone Marrow Transplant; 1997 Aug; 20(3):219-25. PubMed ID: 9257890
[TBL] [Abstract][Full Text] [Related]
20. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]